8-benzyloxy-1-cyano-3,3-dimethyl-6-(5-phenyl-2-pentyloxy)tetralin | 88464-72-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 8-benzyloxy-1-cyano-3,3-dimethyl-6-(5-phenyl-2-pentyloxy)tetralin
• 英文别名: 3,3-dimethyl-8-phenylmethoxy-6-(5-phenylpentan-2-yloxy)-2,4-dihydro-1H-naphthalene-1-carbonitrile
• CAS: 88464-72-6
• 化学式: C₃₁H₃₅NO₂
• 分子量: 453.624
• InChiKey: SMAATPCIIMUIHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Lithium aluminium hydride 、 8-benzyloxy-1-cyano-3,3-dimethyl-6-(5-phenyl-2-pentyloxy)tetralin 、 三氟乙酸酐 、 二苄醚 在 水 、 乙醚 、 magnesium sulfate 、 盐酸 、 碳酸氢钠 、 Brine 、 silica gel 、 methanol-dichloromethane 作用下， 以 三乙胺 、 乙醚 、 四氢呋喃 为溶剂， 反应 2.5h， 以gives 500 mg的产率得到8-Hydroxy-1-trifluoroacetylaminomethyl-3,3-dimethyl-6-(5-phenyl-2-pentyloxy)tetralin
  参考文献：
  名称：

  Benzopyrans

  摘要：

  式为##STR1##的双环融合苯类化合物及其药学上可接受的阳离子和酸性加成盐，其中M为O，CH.sub.2或NR.sub.6; R.sub.6为氢，甲酰基，羧苄氧基或某些羧烷氧基烷基，酰基，烷基，芳基烷基或芳基烷基羰基基团; A'为：(1)当A为氢时，A'为A，其中A和B中的一个为氢，使得当A为氢时，B为C(R.sub.2R.sub.3)(CH.sub.2).sub.fQ，f为1或2;当B为氢时，A为C(R.sub.2R.sub.3)(CH.sub.2).sub.fQ，f为0或1，当A和OR.sub.1一起形成内酯或某些衍生物时; (2)A'为##STR2##(3)A'为Q.sub.3; Q为CO.sub.2R.sub.7，COR.sub.8，C(OH)R.sub.8R.sub.9，CN，CONR.sub.12R.sub.13，CH.sub.2NR.sub.12R.sub.13，CH.sub.2NHCOR.sub.14，CH.sub.2NHSO.sub.2R.sub.17或5-四唑基; Q.sub.3为##STR3##5-四唑基，CH.sub.2CONHCOR.sub.7，COOH或某些酯，酰胺，羧酸亚胺或磺酰亚胺衍生物，CONHOH，CONHCONH.sub.2或COCH.sub.2Q.sub.4，其中Q.sub.4为CN或COOH或某些酯; R.sub.1为氢，苄基或某些酰基; R.sub.4为氢，某些烷基或某些芳基烷基; R.sub.5为氢或某些烷基; Z为(C.sub.1-C.sub.9)烷基，可选地被O，S，SO或SO.sub.2中断; W为氢，甲基，某些芳基或环烷基基团; 在哺乳动物中作为镇痛剂，镇静剂，抗恶心剂，利尿剂，抗癫痫剂，止泻剂，止咳剂，治疗青光眼，以及其中间体。

  公开号：

  US04841078A1

文献信息

• Bicyclic benzo fused compounds
  申请人：Pfizer Inc.

  公开号：US04486428A1

  公开（公告）日：1984-12-04

  Bicyclic fused benzenoid compounds of the formula ##STR1## and pharmaceutically acceptable cationic and acid addition salts thereof, where M is O, CH.sub.2 or NR.sub.6 ; R.sub.6 is hydrogen, formyl, carbobenzyloxy or certain carboalkoxyalkyl, alkanoyl, alkyl, aralkyl or aralkylcarbonyl groups; A' is: (1) A where one of A and B is hydrogen such that when A is hydrogen, B is C(R.sub.2 R.sub.3)(CH.sub.2).sub.f Q and f is 1 or 2; when B is hydrogen, A is C(R.sub.2 R.sub.3)(CH.sub.2).sub.f Q and f is 0 or 1, when taken together A and OR.sub.1 form a lactone or certain derivatives thereof; (2) A' is ##STR2## (3) A' is Q.sub.3 ; Q is CO.sub.2 R.sub.7, COR.sub.8, C(OH)R.sub.8 R.sub.9, CN, CONR.sub.12 R.sub.13, CH.sub.2 NR.sub.12 R.sub.13, CH.sub.2 NHCOR.sub.14, CH.sub.2 NHSO.sub.2 R.sub.17 or 5-tetrazoyl; Q.sub.3 is ##STR3## 5-tetrazolyl, CH.sub.2 CONHCOR.sub.7, COOH or certain ester, amide, carboximido or sulfonimido derivatives thereof, CONHOH, CONHCONH.sub.2, or COCH.sub.2 Q.sub.4 where Q.sub.4 is CN or COOH or certain esters thereof; R.sub.1 is hydrogen, benzyl or certain acyl groups; R.sub.4 is hydrogen, certain alkyl or certain aralkyl groups; R.sub.5 is hydrogen or certain alkyl groups; Z is (C.sub.1 -C.sub.9)alkylene, optionally interrupted by O, S, SO or SO.sub.2 ; and W is hydrogen, methyl, certain aryl or cycloalkyl groups; useful in mammals as analgesics, tranquilizers, antiemetic agents, diuretics, anticonvulsants, antidiarrheals, antitussives, in treatment of glaucoma, and intermediates therefore.

  公式为##STR1##的双环融合苯类化合物及其药学上可接受的阳离子和酸加成盐，其中M为O、CH.sub.2或NR.sub.6；R.sub.6为氢、甲酰基、羧苄氧基或某些羧基烷氧基、烷酰基、烷基、芳基烷基或芳基烷基羰基基团；A'为：(1) A，其中A和B中的一个为氢，使得当A为氢时，B为C(R.sub.2R.sub.3)(CH.sub.2).sub.f Q，f为1或2；当B为氢时，A为C(R.sub.2R.sub.3)(CH.sub.2).sub.f Q，f为0或1，当A和OR.sub.1一起形成内酯或某些衍生物时；(2) A'为##STR2##(3) A'为Q.sub.3；Q为CO.sub.2R.sub.7、COR.sub.8、C(OH)R.sub.8R.sub.9、CN、CONR.sub.12R.sub.13、CH.sub.2NR.sub.12R.sub.13、CH.sub.2NHCOR.sub.14、CH.sub.2NHSO.sub.2R.sub.17或5-四唑基；Q.sub.3为##STR3##5-四唑基、CH.sub.2CONHCOR.sub.7、COOH或某些酯、酰胺、羧酸亚胺或磺酰亚胺衍生物，CONHOH、CONHCONH.sub.2或COCH.sub.2Q.sub.4，其中Q.sub.4为CN或COOH或某些酯；R.sub.1为氢、苄基或某些酰基；R.sub.4为氢、某些烷基或某些芳基烷基；R.sub.5为氢或某些烷基；Z为(C.sub.1-C.sub.9)烷基，可选地由O、S、SO或SO.sub.2中断；W为氢、甲基、某些芳基或环烷基；在哺乳动物中作为镇痛药、镇静剂、止吐剂、利尿剂、抗惊厥药、抗腹泻药、止咳药、治疗青光眼和其中间体。
• Bicyclic benzo fused pyran compounds used for producing analgesia
  申请人：Pfizer Inc.

  公开号：US04863934A1

  公开（公告）日：1989-09-05

  Bicyclic fused benzenoid compounds of the formula ##STR1## and pharmaceutically acceptable cationic and acid addition salts thereof, where M is O, CH.sub.2 or NR.sub.6 ; R.sub.6 is hydrogen, formyl, carbobenzyloxy or certain carboalkoxyalkyl, alkanoyl, alkyl, aralkyl or aralkylcarbonyl groups; A' is: (1) A where one of A and B is hydrogen such that when A is hydrogen, B is C(R.sub.2 R.sub.3)(CH.sub.2).sub.f Q and f is 1 or 2; when B is hydrogen, A is C(R.sub.2 R.sub.3)(CH.sub.2).sub.f Q and f is 0 or 1, when taken together A and OR.sub.1 form a lactone or certain derivatives thereof; (2) A' is ##STR2## (3) A' is Q.sub.3 ; Q is CO.sub.2 R.sub.7, COR.sub.8, C(OH)R.sub.8 R.sub.9, CN, CONR.sub.12 R.sub.13, CH.sub.2 NR.sub.12 R.sub.13, CH.sub.2 NHCOR.sub.14, CH.sub.2 NHSO.sub.2 R.sub.17 or 5-tetrazoyl; Q.sub.3 is ##STR3## 5-tetrazolyl, CH.sub.2 CONHCOR.sub.7, COOH or certain ester, amide, carboximido or sulfonimido derivatives thereof, CONHOH, CONHCONH.sub.2, or COCH.sub.2 Q.sub.4 where Q.sub.4 is CN or COOH or certain esters thereof; R.sub.1 is hydrogen, benzyl or certain acyl groups; R.sub.4 is hydrogen, certain alkyl or certain aralkyl groups; R.sub.5 is hydrogen or certain alkyl groups; Z is (C.sub.1 -C.sub.9)alkylene, optionally interrupted by O, S, SO or SO.sub.2 ; and W is hydrogen, methyl, certain aryl or cycloalkyl groups; useful in mammals as analgesics, tranquilizers, antiemetic agents, diuretics, anticonvulsants, antidiarrheals, antitussives, in treatment of glaucoma, and intermediates therefore.

  公式为##STR1##的双环融合苯类化合物以及其药学上可接受的阳离子和酸加成盐，其中M为O，CH.sub.2或NR.sub.6；R.sub.6为氢，甲酰基，羧苄氧基或某些羧烷氧基烷基，烷酰基，烷基，芳基烷基或芳基烷基羰基基团；A'为：(1)A，其中A和B中的一个为氢，使得当A为氢时，B为C(R.sub.2R.sub.3)(CH.sub.2).sub.fQ，f为1或2；当B为氢时，A为C(R.sub.2R.sub.3)(CH.sub.2).sub.fQ，f为0或1，当A和OR.sub.1一起形成内酯或某些衍生物时；(2)A'为##STR2##(3)A'为Q.sub.3；Q为CO.sub.2R.sub.7，COR.sub.8，C(OH)R.sub.8R.sub.9，CN，CONR.sub.12R.sub.13，CH.sub.2NR.sub.12R.sub.13，CH.sub.2NHCOR.sub.14，CH.sub.2NHSO.sub.2R.sub.17或5-四唑基；Q.sub.3为##STR3##5-四唑基，CH.sub.2CONHCOR.sub.7，COOH或某些酯，酰胺，羧酸亚胺或磺酰亚胺衍生物，CONHOH，CONHCONH.sub.2或COCH.sub.2Q.sub.4，其中Q.sub.4为CN或COOH或某些酯；R.sub.1为氢，苄基或某些酰基；R.sub.4为氢，某些烷基或某些芳基烷基；R.sub.5为氢或某些烷基；Z为(C.sub.1-C.sub.9)烷基，可选地被O，S，SO或SO.sub.2打断；W为氢，甲基，某些芳基或环烷基团；在哺乳动物中作为镇痛剂，镇静剂，止吐剂，利尿剂，抗癫痫剂，止泻剂，止咳剂，治疗青光眼，以及其中间体。
• Bicyclic benzo fused pyran compounds used for nausea treatment and
  申请人：Pfizer Inc.

  公开号：US04870084A1

  公开（公告）日：1989-09-26

  Bicyclic fused benzenoid compounds of the formula ##STR1## and pharmaceutically acceptable cationic and acid addition salts thereof, where M is O, CH.sub.2 or NR.sub.6 ; R.sub.6 is hydrogen, formyl, carbobenzyloxy or certain carboalkoxyalkyl, alkanoyl, alkyl, aralkyl or aralkylcarbonyl groups; A' is: (1) A where one of A and B is hydrogen such that when A is hydrogen, B is C(R.sub.2 R.sub.3)(CH.sub.2).sub.f Q and f is 1 or 2; when B is hydrogen, A is C(R.sub.2 R.sub.3)(CH.sub.2).sub.f Q and f is 0 or 1, when taken together A and OR.sub.1 form a lactone or certain derivatives thereof; (2) A' is ##STR2## (3) A' is Q.sub.3 ; Q is CO.sub.2 R.sub.7, COR.sub.8, C(OH)R.sub.8 R.sub.9, CN, CONR.sub.12 R.sub.13, CH.sub.2 NR.sub.12 R.sub.13, CH.sub.2 NHCOR.sub.14, CH.sub.2 NHSO.sub.2 R.sub.17 or 5-tetrazoyl; Q.sub.3 is ##STR3## 5-tetrazolyl, CH.sub.2 CONHCOR.sub.7, COOH or certain ester, amide, carboximido or sulfonimido derivatives thereof, CONHOH, CONHCONH.sub.2, or COCH.sub.2 Q.sub.4 where Q.sub.4 is CN or COOH or certain esters thereof; R.sub.1 is hydrogen, benzyl or certain acyl groups; R.sub.4 is hydrogen, certain alkyl or certain aralkyl groups; R.sub.5 is hydrogen or certain alkyl groups; Z is (C.sub.1 -C.sub.9) alkylene, optionally interrupted by O, S, SO or SO.sub.2 ; and W is hydrogen, methyl, certain aryl or cycloalkyl groups; useful in mammals as analgesics, tranquilizers, antiemetic agents, diuretics, anticonvulsants, antidiarrheals, antitussives, in treatment of glaucoma, and intermediates therefore.

  公式为 ##STR1## 的双环融合苯类化合物及其药学上可接受的阳离子和酸加成盐，其中M为O，CH.sub.2或NR.sub.6；R.sub.6为氢、甲酰、碳苯甲氧基或某些碳酰基烷氧基、烷酰基、烷基、芳基烷基或芳基烷基羰基基团；A'为：(1)当A为氢时，A'为A，其中A和B中的一个为氢，使得当A为氢时，B为C(R.sub.2R.sub.3)(CH.sub.2).sub.fQ，f为1或2；当B为氢时，A为C(R.sub.2R.sub.3)(CH.sub.2).sub.fQ，f为0或1，当A和OR.sub.1一起时形成内酯或某些衍生物；(2)A'为##STR2##(3)A'为Q.sub.3；Q为CO.sub.2R.sub.7，COR.sub.8，C(OH)R.sub.8R.sub.9，CN，CONR.sub.12R.sub.13，CH.sub.2NR.sub.12R.sub.13，CH.sub.2NHCOR.sub.14，CH.sub.2NHSO.sub.2R.sub.17或5-四唑基；Q.sub.3为##STR3##5-四唑基，CH.sub.2CONHCOR.sub.7，COOH或某些酯、酰胺、羧酸亚胺或磺酰亚胺衍生物，CONHOH，CONHCONH.sub.2或COCH.sub.2Q.sub.4，其中Q.sub.4为CN或COOH或某些酯；R.sub.1为氢、苄基或某些酰基；R.sub.4为氢、某些烷基或某些芳基烷基；R.sub.5为氢或某些烷基；Z为(C.sub.1-C.sub.9)烷基，可选地由O、S、SO或SO.sub.2中断；W为氢、甲基、某些芳基或环烷基基团；在哺乳动物中作为镇痛剂、镇静剂、止吐剂、利尿剂、抗癫痫剂、止泻剂、镇咳剂、治疗青光眼和其中间体。
• US4486428A
  申请人：——

  公开号：US4486428A

  公开（公告）日：1984-12-04
• US4680404A
  申请人：——

  公开号：US4680404A

  公开（公告）日：1987-07-14